Ancillary testing in breast cancer has become standard of care to determine what therapies may be most effective for individual patients with breast cancer. Single-marker tests are required on all newly diagnosed and newly metastatic breast cancers. Markers of proliferation are also used, and include both single-marker tests like Ki67 as well as panel-based gene expression tests, which have made more recent contributions to prognostic and predictive testing in breast cancers. This review focuses on pathologist interpretation of these ancillary test results, with a focus on expected versus unexpected results and troubleshooting borderline, unusual, or discordant results.
Keywords: Breast cancer; ER testing; Fluorescence in situ hybridization (FISH); HER2 testing; Molecular testing; OncotypeDX; Predictive testing.
Copyright © 2017 Elsevier Inc. All rights reserved.